Trial Profile
Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- 15 Oct 2015 Primary end points has been changed as reported by ClinicalTrials.gov record.
- 30 Dec 2014 New trial record